AU2022265461A1 - Molephantin derivatives useful in the treatment of cancer - Google Patents

Molephantin derivatives useful in the treatment of cancer Download PDF

Info

Publication number
AU2022265461A1
AU2022265461A1 AU2022265461A AU2022265461A AU2022265461A1 AU 2022265461 A1 AU2022265461 A1 AU 2022265461A1 AU 2022265461 A AU2022265461 A AU 2022265461A AU 2022265461 A AU2022265461 A AU 2022265461A AU 2022265461 A1 AU2022265461 A1 AU 2022265461A1
Authority
AU
Australia
Prior art keywords
cancer
alkyl
substituted
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022265461A
Other languages
English (en)
Inventor
Shunsuke CHIBA
Cheng Gee KOH
Soak Kuan LAI
Hoi Yeung LI
Toon Wah Roland ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Biologics Pte Ltd
Original Assignee
Nanyang Biologics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Biologics Pte Ltd filed Critical Nanyang Biologics Pte Ltd
Publication of AU2022265461A1 publication Critical patent/AU2022265461A1/en
Assigned to NANYANG TECHNOLOGICAL UNIVERSITY, NANYANG BIOLOGICS PTE. LTD. reassignment NANYANG TECHNOLOGICAL UNIVERSITY Request for Assignment Assignors: NANYANG HERBS PTE. LTD., NANYANG TECHNOLOGICAL UNIVERSITY
Assigned to NANYANG BIOLOGICS PTE. LTD. reassignment NANYANG BIOLOGICS PTE. LTD. Request for Assignment Assignors: NANYANG BIOLOGICS PTE. LTD., NANYANG TECHNOLOGICAL UNIVERSITY
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022265461A 2021-04-29 2022-04-27 Molephantin derivatives useful in the treatment of cancer Pending AU2022265461A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202104429U 2021-04-29
SG10202104429U 2021-04-29
PCT/SG2022/050251 WO2022231520A1 (en) 2021-04-29 2022-04-27 Molephantin derivatives useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2022265461A1 true AU2022265461A1 (en) 2023-11-16

Family

ID=83848883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022265461A Pending AU2022265461A1 (en) 2021-04-29 2022-04-27 Molephantin derivatives useful in the treatment of cancer

Country Status (7)

Country Link
US (1) US20250304544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4330241A4 (cg-RX-API-DMAC7.html)
JP (1) JP7897576B2 (cg-RX-API-DMAC7.html)
CN (1) CN117377663A (cg-RX-API-DMAC7.html)
AU (1) AU2022265461A1 (cg-RX-API-DMAC7.html)
IL (1) IL308058A (cg-RX-API-DMAC7.html)
WO (1) WO2022231520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919833A (zh) * 2023-01-31 2023-04-07 暨南大学附属第一医院(广州华侨医院) 一种CutC蛋白抑制剂及其应用
AU2024337402A1 (en) * 2023-09-06 2026-03-26 Nanyang Biologics Pte. Ltd. Collective synthesis of phantomolin family through total synthesis of the sesquiterpene lactone molephantin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3418724B2 (ja) * 2000-02-10 2003-06-23 国立医薬品食品衛生研究所長 セスキテルペノイド化合物及びそれを含む医薬
JP2005002050A (ja) * 2003-06-12 2005-01-06 Shiseido Co Ltd 美白剤及びこれを配合した皮膚外用剤
CN102000072A (zh) * 2009-09-01 2011-04-06 奇复康药物研发(苏州)有限公司 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
CN103732586B (zh) * 2011-04-07 2016-02-03 南洋理工大学 作为抗癌剂的乙酰基丹参酮iia(ata)
US11634400B2 (en) 2017-08-19 2023-04-25 University Of Rochester Micheliolide derivatives, methods for their preparation and their use as anticancer and antiinflammatory agents
CN111153910B (zh) * 2020-01-09 2021-07-30 沈阳药科大学 地胆草种内酯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US20250304544A1 (en) 2025-10-02
IL308058A (en) 2023-12-01
JP7897576B2 (ja) 2026-07-30
JP2024517443A (ja) 2024-04-22
CN117377663A (zh) 2024-01-09
EP4330241A1 (en) 2024-03-06
WO2022231520A1 (en) 2022-11-03
EP4330241A4 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
ES2749096T3 (es) Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados
ES2965675T3 (es) Antagonistas del receptor NK-3 para el tratamiento terapéutico o cosmético del exceso de grasa corporal
TWI564291B (zh) 一氧化氮生成調節劑
EP3908570B1 (en) Ketamine pamoate and use thereof
US20250304544A1 (en) Molephantin derivatives useful in the treatment of cancer
EP3570940A1 (en) Use of pridopidine for the treatment of fragile x syndrome
JP2024510249A (ja) 神経疾患を治療するための組成物およびその方法
AU2006216031A1 (en) Anti-tumor agent
PT94713A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um derivado heteroaril-3-oxo-propanonitrilico como ingrediente activo capazes de estimular a mielopoese em mamiferos
CN105189446B (zh) 间苯三酚类衍生物及其在治疗神经退行性疾病中的用途
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
AU2017221673B2 (en) Novel indole derivative and anti-cancer composition containing same
WO2019052477A1 (zh) 丹参酮类化合物及其用于治疗血管瘤的用途
CN117136050A (zh) 用于使用大麻素治疗神经元病症的组合物和方法
WO2025043213A2 (en) Therapeutic compounds and methods
BRPI0718904A2 (pt) Pirrol[1,2-a] imidazolodiona efetiva no tratamento de neurotoxicidade induzida por agentes quimioterapêuticos
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CN117797134A (zh) 一种4-tmap治疗或缓解抑郁症的用途
CN110709079B (zh) 包含1,2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物
KR20230061528A (ko) 구강 건조증의 치료에 사용하기 위한 화합물
CN108503651B (zh) 一种用于治疗脑卒中的螺环化合物
CN106554349A (zh) 野八角新异戊烯基取代c6‑c3类化合物及其制备方法、应用和其药物组合物
CN116987091B (zh) 用于治疗癫痫发作疾病的药物及其制备方法
CA3118954C (en) Ketamine pamoate and use thereof
KR100379155B1 (ko) 새로운 진통제 조성물

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NANYANG TECHNOLOGICAL UNIVERSITY

Free format text: FORMER APPLICANT(S): NANYANG TECHNOLOGICAL UNIVERSITY; NANYANG HERBS PTE. LTD.

Owner name: NANYANG BIOLOGICS PTE. LTD.

Free format text: FORMER APPLICANT(S): NANYANG TECHNOLOGICAL UNIVERSITY; NANYANG HERBS PTE. LTD.

PC1 Assignment before grant (sect. 113)

Owner name: NANYANG BIOLOGICS PTE. LTD.

Free format text: FORMER APPLICANT(S): NANYANG BIOLOGICS PTE. LTD.; NANYANG TECHNOLOGICAL UNIVERSITY